Orpea


Now double risks on Orpea’s reliable business model

25/03/20 -"Orpea once again announced in line and supportive FY results. We remain confident in its solid fundamentals. However, we worry about the extent the current Coronavirus pandemic could affect the ..."

Pages
44
Language
English
Published on
25/03/20
You may also be interested by these reports :
30/03/20
Sartorius (Reduce, Germany), a Göttingen-based bioprocessing equipment manufacturer (largely through subsidiary Sartorius Stedim), has been an ace ...

27/03/20
Our DCF valuation moves significantly higher on account of: 1. the integration of Biological Industries and Danaher assets’ acquisitions; 2. the ...

27/03/20
In an environment where the majority of the MedTech stocks have been bashed relentlessly in the past month, Qiagen has been an exception. A takeover ...

25/03/20
Orpea once again announced in line and supportive FY results. We remain confident in its solid fundamentals. However, we worry about the extent the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO